

# Donal T Skelly

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3557210/donal-t-skelly-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41  
papers

2,950  
citations

24  
h-index

49  
g-index

49  
ext. papers

5,460  
ext. citations

25.3  
avg, IF

4.68  
L-index

#	Paper	IF	Citations
41	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. <i>Cell</i> , <b>2022</b> ,	56.2	154
40	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. <i>Cell</i> , <b>2022</b> , 185, 916-938.e58	56.2	17
39	Divergent trajectories of antiviral memory after SARS-CoV-2 infection.. <i>Nature Communications</i> , <b>2022</b> , 13, 1251	17.4	1
38	A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.. <i>Journal of Immunological Methods</i> , <b>2022</b> , 504, 113263	2.5	
37	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <b>2021</b> ,		25
36	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , <b>2021</b> ,	22.2	29
35	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. <i>Cell Host and Microbe</i> , <b>2021</b> ,	23.4	14
34	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , <b>2021</b> , 184, 5699-5714.e11	56.2	64
33	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , <b>2021</b> , 12, 1951	17.4	25
32	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , <b>2021</b> , 12, 2055	17.4	37
31	A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
30	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , <b>2021</b> , 184, 2183-2200.e22	56.2	145
29	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , <b>2021</b> , 184, 2348-2361.e6	56.2	549
28	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , <b>2021</b> , 184, 2201-2211.e7	56.2	269
27	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2939-2954.e9	56.2	281
26	Double stranded RNA drives anti-viral innate immune responses, sickness behavior and cognitive dysfunction dependent on dsRNA length, IFNAR1 expression and age. <i>Brain, Behavior, and Immunity</i> , <b>2021</b> , 95, 413-428	16.6	7
25	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	31

24	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , <b>2021</b> , 184, 4220-4236.e13		
23	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , <b>2021</b> , 12, 5061	17.4	42
22	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009804	7.6	7
21	Double stranded RNA drives innate immune responses, sickness behavior and cognitive impairment dependent on dsRNA length, IFNAR1 expression and age <b>2021</b> ,		2
20	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e699-e709	11.6	120
19	Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.. <i>Gut</i> , <b>2021</b> ,	19.2	0
18	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 139	4.8	120
17	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 181	4.8	38
16	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 181	4.8	60
15	Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. <i>ELife</i> , <b>2020</b> , 9,	8.9	122
14	Author response: Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study <b>2020</b> ,		4
13	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 1390-1400	25.5	212
12	Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms. <i>Molecular Psychiatry</i> , <b>2019</b> , 24, 1533-1548	15.1	52
11	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel		55
10	Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study		6
9	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses		7
8	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14
7	Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.		7

6	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses		6
5	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity		4
4	Divergent trajectories of antiviral memory after SARS-Cov-2 infection		4
3	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> ,	1	2
2	Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.		27
1	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum		3